scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1013604887 |
P356 | DOI | 10.1007/S10549-013-2460-Y |
P698 | PubMed publication ID | 23479421 |
P50 | author | Michael P. Lux | Q37372079 |
Stefan P Renner | Q51833341 | ||
Alexander Hein | Q52723502 | ||
Peter A. Fasching | Q64005064 | ||
Matthias W. Beckmann | Q72940290 | ||
Lothar Haeberle | Q87976657 | ||
Arndt Hartmann | Q89782316 | ||
Michael G Schrauder | Q90107267 | ||
Katharina Heusinger | Q114387418 | ||
Christian M Bayer | Q124154078 | ||
P2093 | author name string | Christian R Loehberg | |
Mayada R Bani | |||
Sebastian M Jud | |||
Falk C Thiel | |||
David L Wachter | |||
Katrin Almstedt | |||
Carolin C Hack | |||
Jutta Heimrich | |||
Michaela Brunner | |||
P2860 | cites work | ZNF703 gene amplification at 8p12 specifies luminal B breast cancer | Q24293333 |
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium | Q24293658 | ||
Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer | Q33813431 | ||
Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis | Q33903716 | ||
Estrogen and progestin regulation of cell cycle progression | Q33923687 | ||
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies | Q33984087 | ||
Clinical course and prognostic factors following bone recurrence from breast cancer | Q34065927 | ||
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment | Q34074094 | ||
Receptor conversion in distant breast cancer metastases | Q34989060 | ||
Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss | Q35082619 | ||
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis | Q35546265 | ||
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group | Q35552069 | ||
Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors | Q35558018 | ||
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis | Q35558914 | ||
The biology of progesterone receptor in the normal mammary gland and in breast cancer | Q35868802 | ||
Survival after first recurrence of breast cancer. The Miami experience | Q36215855 | ||
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer | Q36393082 | ||
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. | Q36924473 | ||
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer | Q37198196 | ||
Prognostic factors in 1,038 women with metastatic breast cancer | Q37321930 | ||
Ki67 in breast cancer: prognostic and predictive potential | Q37691691 | ||
Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases | Q40504026 | ||
Construction and validation of a practical prognostic index for patients with metastatic breast cancer | Q40851122 | ||
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. | Q43447818 | ||
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy | Q43542643 | ||
Progesterone receptor status of breast cancer metastases | Q43893980 | ||
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register | Q44248479 | ||
Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer | Q44287591 | ||
Impact of metastatic estrogen receptor and progesterone receptor status on survival | Q46382088 | ||
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. | Q50510241 | ||
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial. | Q51652478 | ||
Multivariate analysis of prognostic factors in metastatic breast cancer. | Q52699716 | ||
Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. | Q54400297 | ||
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. | Q54519817 | ||
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. | Q54614183 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 899-908 | |
P577 | publication date | 2013-03-12 | |
P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
P1476 | title | Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis | |
P478 | volume | 138 |
Q38374808 | ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis |
Q35054455 | Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network |
Q27014939 | Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies |
Q49796329 | Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. |
Q36273328 | Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast |
Q36892788 | Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry |
Q53599540 | Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients. |
Q37309686 | SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer |
Q42599064 | Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors |
Q35619770 | The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients |
Q96432540 | Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer |
Q44521334 | Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility |
Q52848499 | [New prognostic and predictive markers for breast cancer]. |
Search more.